rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

TransCode Therapeutics, Inc.

RNAZ · Nasdaq

Health CareBiotechnologyNot moving yet

RNAZ stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 69.0% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
9 (+2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders9+2 on the quarter
New · exited3 · 1
Reported value$218K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Yorkville Advisors Global, LPnew · filed 6 Aug 202619,639$122K+19,639
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 20266,545$41K00.0%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 20262,982$19K00.0%
UBS Group AGreduced · filed 13 Aug 20262,888$18K-5,407−65.2%
MERCER GLOBAL ADVISORS INCnew · filed 11 Aug 20261,535$9,532+1,535
FMR LLCnew · filed 13 Aug 2026706$4,384+706
Tower Research Capital LLC (TRC)added · filed 11 Aug 2026677$4,204+449+196.9%
WELLS FARGO & COMPANYunchanged · filed 14 Aug 202655$34200.0%
SBI Securities Co., Ltd.unchanged · filed 23 Jul 202612$7500.0%
31 Dec 2024 – 30 Jun 2026
51014Dec 24Jun 25Sep 25Mar 26Jun 26

Everyone who traded it

Thomas A. Fitzgerald Company insiderChief Financial Officer · last 9 Sep 20262 · 0
Ck Life Sciences Intl (Holdings) Inc Company insider10% owner · last 3 Aug 20260 · 0
DEFJ, LLC Company insider10% owner · last 3 Aug 20260 · 0
Erik Manting Company insiderDirector · last 14 Jun 20240 · 0
Magda Marquet Company insiderDirector · last 14 Jun 20240 · 0
Philippe Calais Company insiderDirector · last 14 Jun 20240 · 0
Robert Michael Dudley Company insiderChief Executive Officer · last 28 Sep 20238 · 0
Zdravka Medarova Company insiderChief Technology Officer · last 12 Dec 20220 · 0

Same industry

MRNA ModernaLeading+147%
IOVA Iovance BiotherapeuticsLeading+126%
ABCL AbCellera BiologicsLeading+60%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+38%
ENTX Entera BioLeading+37%
HELP Helus PharmaLeading+36%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-17.6%
Share count trendFY 2025 · to 3 Apr 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$17.8M
Free cash flowFY 2025 · to 31 Dec 2025−$19.5M

Analyst forecasts

No analyst forecasts yet.